|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
|
MXPA98000395A
(es)
|
1995-07-14 |
2005-04-29 |
Medeva Europ Ltd |
Composicion que comprende d-treo-metilfenidato y otra droga.
|
|
US7081238B2
(en)
*
|
1995-11-03 |
2006-07-25 |
The President And Fellows Of Harvard College |
Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
|
|
US5733756A
(en)
*
|
1996-01-05 |
1998-03-31 |
Celgene Corporation |
Lactams and processes for stereoselective enrichment of lactams, amides, and esters
|
|
US5908850A
(en)
*
|
1995-12-04 |
1999-06-01 |
Celgene Corporation |
Method of treating attention deficit disorders with d-threo methylphenidate
|
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
|
US6355656B1
(en)
|
1995-12-04 |
2002-03-12 |
Celgene Corporation |
Phenidate drug formulations having diminished abuse potential
|
|
US6919373B1
(en)
*
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
|
US6962997B1
(en)
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
|
US20020102291A1
(en)
*
|
1997-12-15 |
2002-08-01 |
Noven Pharmaceuticals, Inc. |
Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
|
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
|
PL205109B1
(pl)
|
1998-11-02 |
2010-03-31 |
Elan Pharma Int Ltd |
Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
|
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
|
US7083808B2
(en)
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
|
US6127385A
(en)
*
|
1999-03-04 |
2000-10-03 |
Pharmaquest Limited |
Method of treating depression using l-threo-methylphenidate
|
|
US6395752B1
(en)
*
|
1999-03-04 |
2002-05-28 |
Pharmaquest Limited |
Method of treating depression using 1-threo-methylphenidate
|
|
WO2000059481A1
(en)
|
1999-04-06 |
2000-10-12 |
Pharmaquest Ltd. |
PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
|
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
|
US7553478B2
(en)
*
|
1999-05-12 |
2009-06-30 |
President And Fellows Of Harvard College |
Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
|
|
GB9913458D0
(en)
*
|
1999-06-09 |
1999-08-11 |
Medeva Europ Ltd |
The therapeutic use of d-threo-methylphenidate
|
|
US20100143248A1
(en)
*
|
1999-06-28 |
2010-06-10 |
President And Fellows Of Harvard College |
Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
|
|
EP2305218A1
(en)
|
1999-10-29 |
2011-04-06 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
JP3856283B2
(ja)
*
|
2000-02-14 |
2006-12-13 |
シャープ株式会社 |
固体撮像装置および撮像装置の駆動方法
|
|
US6221883B1
(en)
*
|
2000-04-12 |
2001-04-24 |
Ross Baldessarini |
Method of dopamine inhibition using l-threo-methylphenidate
|
|
DE60027282T2
(de)
*
|
2000-06-17 |
2007-04-12 |
Pharmaquest Ltd., Hamilton |
Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
|
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
|
CN103690540A
(zh)
|
2000-10-30 |
2014-04-02 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
|
US20020187192A1
(en)
*
|
2001-04-30 |
2002-12-12 |
Yatindra Joshi |
Pharmaceutical composition which reduces or eliminates drug abuse potential
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US20030049272A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Yatindra Joshi |
Pharmaceutical composition which produces irritation
|
|
US6638533B2
(en)
|
2002-01-03 |
2003-10-28 |
George Krsek |
Pulse dosage formulations of methylphenidate and method to prepare same
|
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
|
US7988993B2
(en)
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
|
WO2006063078A2
(en)
*
|
2004-12-08 |
2006-06-15 |
Elan Corporation, Plc |
Topiramate pharmaceuticals composition
|
|
EP1830648A4
(en)
*
|
2004-12-09 |
2008-03-12 |
Celgene Corp |
TREATMENT WITH D-THREO-METHYLPHENIDATE
|
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
AU2006235483B2
(en)
*
|
2005-04-12 |
2010-11-25 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
|
KR101495146B1
(ko)
|
2006-03-16 |
2015-02-24 |
트리스 파마 인코포레이티드 |
약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
|
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
|
WO2011020032A2
(en)
*
|
2009-08-13 |
2011-02-17 |
Kudco Ireland, Ltd. |
Pharmaceutical dosage form
|
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
EP4316488A3
(en)
|
2011-03-23 |
2024-02-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods and compositions for treatment of attention deficit disorder
|
|
ES2717469T3
(es)
|
2012-08-15 |
2019-06-21 |
Tris Pharma Inc |
Comprimido masticable de metilfenidato de liberación prolongada
|
|
CA2902911C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
KR102174787B1
(ko)
|
2018-11-14 |
2020-11-05 |
호서대학교 산학협력단 |
재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
|
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|